Tandem Versus Single Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma in the Era of Novel Agents: A Real-World Study of China

Overview

Journal Cancer Med

Specialty Oncology

Date 2025 Jan 2

PMID 39744915

Authors

Xuelin Dou

Juan Ren

Jiangtao Li

Xiaodan Liu

Li Bao

Yuan Chen

Peng Zhao

Yuping Zhong

Nan Peng

Lei Wen

Leqing Cao

Yang Liu

Daoxing Deng

Fengrong Wang

Liru Wang

Hui Liu

Xiaojun Huang

Xiaodong Mo

Jin Lu

Affiliations

Soon will be listed here.

Abstract

Background: This study compares the efficacy and safety of single autologous stem cell transplantation (ASCT) versus tandem ASCT for multiple myeloma (MM) patients in the era of novel agents.

Methods: A total of 112 high-risk MM patients were included (single ASCT, (n = 57) or tandem ASCT(n = 55) in this retrospective multicenter study. Responses and outcomes were evaluated.

Results: At 100 days after ASCT1 and ASCT2, 36 (63.2%) versus 45 (81.8%) patients achieved sCR/CR, 16 (28.1%) versus 7 (12.7%) patients achieved VGPR, and 5 (8.8%) versus 1 (1.8%) patient achieved PR, respectively, in the single and tandem ASCT cohorts. The 3-year cumulative incidence of non-relapse mortality and disease progression was 0% versus 7.3% (p = 0.083), and 45.8% versus 25.8% (p = 0.039), respectively, for the single and tandem ASCT cohort. The tandem ASCT cohort showed a trend of better 3-year probability of PFS (58.1% vs. 64.7%, p = 0.064) compared with the single ASCT cohort. In multivariate analysis, ultra high-risk and achieving<VGPR response after ASCT1 were associated with an inferior PFS. Ultra high-risk was also associated with an inferior OS.

Conclusions: Tandem ASCT demonstrated improved outcomes compared to single ASCT in high-risk MM patients receiving triplet or quadruplet induction and maintenance therapy. However, patients with ultra high-risk cytogenetics may require innovative therapeutic approaches, as tendem ASCT does not overcome their adverse prognosis.

References

Gagelmann N, Eikema D, Koster L, Caillot D, Pioltelli P, Lleonart J . Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and.... Biol Blood Marrow Transplant. 2019; 25(11):2134-2142. DOI: 10.1016/j.bbmt.2019.07.004. View

Rajkumar S, Dimopoulos M, Palumbo A, Blade J, Merlini G, Mateos M . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-48. DOI: 10.1016/S1470-2045(14)70442-5. View

Banerjee R, Cicero K, Lee S, Cowan A . Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling. Front Oncol. 2023; 13:1240966. PMC: 10577204. DOI: 10.3389/fonc.2023.1240966. View

Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L . Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2013; 99(2):360-4. PMC: 3912968. DOI: 10.3324/haematol.2013.094409. View

Attal M, Harousseau J, Facon T, Guilhot F, Doyen C, Fuzibet J . Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003; 349(26):2495-502. DOI: 10.1056/NEJMoa032290. View

Huang J, Chan S, Lok V, Zhang L, Lucero-Prisno 3rd D, Xu W . The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022; 9(9):e670-e677. DOI: 10.1016/S2352-3026(22)00165-X. View

Kumar A, Kharfan-Dabaja M, Glasmacher A, Djulbegovic B . Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009; 101(2):100-6. DOI: 10.1093/jnci/djn439. View

Villalba A, Gonzalez-Rodriguez A, Arzuaga-Mendez J, Puig N, Arnao M, Arguinano J . Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM). Leuk Lymphoma. 2022; 63(14):3438-3447. DOI: 10.1080/10428194.2022.2123229. View

Bazarbachi A, Al Hamed R, Malard F, Bazarbachi A, Harousseau J, Mohty M . Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer J. 2022; 12(3):47. PMC: 8960754. DOI: 10.1038/s41408-022-00645-1. View

10.

Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F . Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007; 25(17):2434-41. DOI: 10.1200/JCO.2006.10.2509. View

11.

Stadtmauer E, Pasquini M, Blackwell B, Hari P, Bashey A, Devine S . Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. J Clin Oncol. 2019; 37(7):589-597. PMC: 6553842. DOI: 10.1200/JCO.18.00685. View

12.

Mai E, Benner A, Bertsch U, Brossart P, Hanel A, Kunzmann V . Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol. 2016; 173(5):731-41. DOI: 10.1111/bjh.13994. View

13.

Suzuki K, Shimazu Y, Minakata D, Ikeda T, Takahashi H, Tsukada N . Efficacy of Autologous Stem Cell Transplantation for Myeloma Patients with Suboptimal Response: A Multicenter Retrospective Analysis. Transplant Cell Ther. 2023; 29(11):688.e1-688.e13. DOI: 10.1016/j.jtct.2023.08.006. View

14.

Batsukh K, Lee S, Min G, Park S, Jeon Y, Yoon J . Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma. Immune Netw. 2017; 17(4):250-260. PMC: 5577302. DOI: 10.4110/in.2017.17.4.250. View

15.

Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M . Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide.... Lancet Oncol. 2021; 22(12):1705-1720. DOI: 10.1016/S1470-2045(21)00535-0. View

16.

Sonneveld P, van der Holt B, Segeren C, Vellenga E, Croockewit A, Verhoe G . Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica. 2007; 92(7):928-35. DOI: 10.3324/haematol.11168. View

17.

Cavo M, Gay F, Beksac M, Pantani L, Petrucci M, Dimopoulos M . Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95):.... Lancet Haematol. 2020; 7(6):e456-e468. DOI: 10.1016/S2352-3026(20)30099-5. View

18.

Zamagni E, Barbato S, Cavo M . How I treat high-risk multiple myeloma. Blood. 2021; 139(19):2889-2903. DOI: 10.1182/blood.2020008733. View

19.

Naumann-Winter F, Greb A, Borchmann P, Bohlius J, Engert A, Schnell R . First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev. 2012; 10:CD004626. PMC: 11495656. DOI: 10.1002/14651858.CD004626.pub3. View

20.

Garces J, Cedena M, Puig N, Burgos L, Perez J, Cordon L . Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. J Clin Oncol. 2022; 40(27):3151-3161. DOI: 10.1200/JCO.21.01365. View